[go: up one dir, main page]

CL2009000660A1 - Use of a protease-activated receptor 2 (par2) antagonist to treat, inhibit, or relieve pain. - Google Patents

Use of a protease-activated receptor 2 (par2) antagonist to treat, inhibit, or relieve pain.

Info

Publication number
CL2009000660A1
CL2009000660A1 CL2009000660A CL2009000660A CL2009000660A1 CL 2009000660 A1 CL2009000660 A1 CL 2009000660A1 CL 2009000660 A CL2009000660 A CL 2009000660A CL 2009000660 A CL2009000660 A CL 2009000660A CL 2009000660 A1 CL2009000660 A1 CL 2009000660A1
Authority
CL
Chile
Prior art keywords
par2
antagonist
protease
inhibit
treat
Prior art date
Application number
CL2009000660A
Other languages
Spanish (es)
Inventor
Lynn Macdonald
Richard Torres
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2009000660A1 publication Critical patent/CL2009000660A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor.Use of a protease-activated receptor 2 (par2) antagonist to treat, inhibit, or relieve pain.

CL2009000660A 2008-03-19 2009-03-18 Use of a protease-activated receptor 2 (par2) antagonist to treat, inhibit, or relieve pain. CL2009000660A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790808P 2008-03-19 2008-03-19
US11915508P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
CL2009000660A1 true CL2009000660A1 (en) 2010-04-16

Family

ID=40718925

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000660A CL2009000660A1 (en) 2008-03-19 2009-03-18 Use of a protease-activated receptor 2 (par2) antagonist to treat, inhibit, or relieve pain.

Country Status (6)

Country Link
AR (1) AR070911A1 (en)
CL (1) CL2009000660A1 (en)
PE (1) PE20091693A1 (en)
TW (1) TW201002345A (en)
UY (1) UY31723A (en)
WO (1) WO2009117481A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591389B2 (en) 2017-03-16 2023-02-28 Medimmune Limited Nucleic acids encoding anti-PAR2 antibodies and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214655B2 (en) * 2001-05-21 2007-05-08 Johnson & Johnson Consumer Companies, Inc. Peptides and the use thereof in darkening the skin
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (en) 2009-09-09 2018-03-08 Regeneron Pharma High affinity human antibodies to human protease-activated receptor-2
AU2012331140A1 (en) 2011-11-04 2014-05-08 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
CN109152777A (en) * 2016-05-20 2019-01-04 武田药品工业株式会社 The treatment of pain
US20190201454A1 (en) * 2016-06-23 2019-07-04 Mayo Foundation For Medical Education And Research Par2 modulation to alter myelination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629174A (en) * 1993-07-26 1997-05-13 Cor Therapeutics, Inc. Recombinant C140 receptor
NZ302524A (en) * 1995-01-25 1999-05-28 Cor Therapeutics Inc Dna encoding the c140 receptor, agonists and antagonists therefor and use in assays to detect vascular pressure abnormalities
AU2005254155A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591389B2 (en) 2017-03-16 2023-02-28 Medimmune Limited Nucleic acids encoding anti-PAR2 antibodies and uses thereof

Also Published As

Publication number Publication date
UY31723A (en) 2009-11-10
WO2009117481A1 (en) 2009-09-24
TW201002345A (en) 2010-01-16
PE20091693A1 (en) 2009-11-16
AR070911A1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
CL2009000660A1 (en) Use of a protease-activated receptor 2 (par2) antagonist to treat, inhibit, or relieve pain.
ECSP11011459A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
CL2008001114A1 (en) Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
ECSP13012573A (en) 6-amino-nicotinamides substituted as modulators of KCNQ2 / 3
UY32085A (en) KINASE INHIBITORS AND METHODS FOR USE
NI201000044A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
CR10309A (en) "COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1"
ECSP088874A (en) USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE POSMENOPAUSIC DISORDERS
CO6400170A2 (en) AGOSNISTS AND ANTAGONISTS OF THE S1P5 RECEIVER AND METHODS OF USE OF THE SAME
ECSP11011127A (en) ANTI-cMET NEW ANTIBODY
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
CL2008000418A1 (en) Use of an il-23 antagonist for the treatment of a fungal infection.
BR112013001613A2 (en) tricyclic compounds and methods for making and using them.
CY1115852T1 (en) PHARMACEUTICAL COMPOSITIONS
CL2011000544A1 (en) Compounds derived from benzamide n substituted by heterocycle, cannabinoid receptor ligands; pharmaceutical composition; and its use to treat pain, among other diseases.
CR11264A (en) COMPOUNDS OF 5- (4-HALO-ALCOXI) -PENYL) -PIRIMIDIN-2-AMINA AND COMPOSITIONS AS KINASE INHIBITORS
CL2015002534A1 (en) Combined formulations of neosaxitoxin for prolonged local anesthesia
NI201000015A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
EA201171074A1 (en) CYTOTOXIC CONJUGATES WITH CONNECTION, BINDING THE NEUROPEPTIDE Y RECEPTOR
CL2012002551A1 (en) Pharmaceutical combination comprising at least one 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol of formula (i) and at least one nmda antagonist; pharmaceutical composition; and use for pain treatment.
ECSP13012453A (en) 2-oxy-quinoline-3-carboxamides substituted as KCNQ2 / 3 modulators
CL2011001026A1 (en) Use of pimobedan to prepare a useful medication in the treatment of hypertrophic cardiomyopathy in a cat.
CL2007003251A1 (en) Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.
PA8814801A1 (en) TRIAZOLOPIRIDAZINAS AS PAR1 INHIBITORS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
ECSP088939A (en) CARBOXAMIDS REPLACED AS ANTAGONISTS OF THE METABOTROPIC RECEIVER OF GROUP I